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Atopic dermatitis (AD) is a common chronic inflammatory skin disorder, and patients
with AD suffer from severe psychological stress, which markedly increases the
prevalence rate of depression and anxiety disorders in later life. Fluoxetine, a selective
serotonin reuptake inhibitor, has recently been reported to exert anti-inflammatory and
immunosuppressive effects. However, it is unclear whether fluoxetine is effective in the
treatment of AD through reducing psychological stress and inflammatory reaction. Here,
we reported that a BALB/c mouse model of AD was induced by application of 2,4-
dinitrochlorobenzene (DNCB) onto hairless dorsal skin. Chronic fluoxetine treatment
(10 mg/kg per day, i.p.) significantly attenuated AD-like symptoms, as reflected by
a dramatic decrease in scratching bouts, as well as a decrease in anxiety- and
depressive-like behaviors. Furthermore, these behavioral changes were accompanied
by a significant decrease in epidermal thickness, the number of mast cells in skin
tissue, mRNA levels of interleukin-4 (IL-4) and IL-13 in the spleen, as well as serum
immunoglobulin E (IgE) in the DNCB-treated mice by treatment with fluoxetine. Taken
together, these results indicate that fluoxetine may suppress psychological stress
and inflammatory response during AD development, and subsequently ameliorate AD
symptoms, suggesting that fluoxetine may be a potential therapeutic agent against AD
in clinic.
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INTRODUCTION
Atopic dermatitis (AD), also known as atopic eczema, is a common chronic inflammatory skin
disease that is characterized by intense itching and recurrent eczematous lesions. The prevalence
rate of AD is rising dramatically, especially in developed countries, and it now affects 10–30%
of children and 1–10% of adults (Leung et al., 2004; Montes-Torres et al., 2015; Weidinger
and Novak, 2015), leading to a significant reduction in quality of life and economic burden
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(Berke et al., 2012). The pathogenesis of AD is not very clear, but
it seems to be correlated with specific immune and inflammatory
mechanisms. It has been reported that repeated applications
of 2,4-dinitrochlorobenzene (DNCB) to mouse skin induced
AD-like skin lesions, which is associated with a significant
increase in serum immunoglobulin E (IgE) and T-helper (Th) 2
cytokines such as interleukin-4 (IL-4) and IL-13 at the chronic
dermatitis site (Kitagaki et al., 1995; Harada et al., 2005). Further
clinic studies have shown that these immunological changes
are also observed in patients with AD (Leung et al., 2004; Liu
et al., 2011). Therefore, most cases of AD currently are treated
with emollients and topical anti-inflammatory agents such as
topical corticosteroids and the topical calcineurin inhibitors.
Many patients can be managed effectively, however, considerable
number of patients still suffers from relapsing intolerable AD. In
addition, these pharmacological therapies may cause various side
effects including skin atrophy, telangiectases, purpura, and striae
formation (Del Rosso and Friedlander, 2005). Thus, the use of less
toxic alternative therapeutic agent against AD is imperative.
Meanwhile, a growing body of evidence has shown that
patients with AD suffer from a severe psychological stress, which
markedly increases the prevalence rate of depression and anxiety
disorders (Wahlgren, 1992; Ginsburg et al., 1993; Hashiro and
Okumura, 1997; Cheng et al., 2015), and in turn, stress may
aggravate AD symptoms. Thus, reduction of depressive- and/or
anxiety-related emotions by inhibiting psychological stress may
be a potential method for the treatment of AD. Indeed, previous
studies have shown that paroxetine, a selective serotonin reuptake
inhibitor (SSRI), is effective in the treatment of AD-like lesions
in NC/Nga mice and chronic pruritus in patients (Zylicz et al.,
2003; Jiang et al., 2007; Stander et al., 2009). Our recent study
has reported that another SSRI fluoxetine, which has been
widely used as an antidepressant agent in clinic, displayed anti-
stress effects (Han et al., 2015). Furthermore, fluoxetine has also
shown anti-inflammatory and direct immunosuppressive effects
such as suppression of T cell activation, cytokine secretion and
proliferation and induction of apoptosis in vitro and in vivo
(Janssen et al., 2010; Gobin et al., 2013, 2014). Thus, it is
reasonable to propose that fluoxetine may ameliorate AD through
reducing psychological stress and inflammatory response.
To test this hypothesis, we treated BALB/c mice with DNCB to
induce human AD-like skin lesions, and assessed the inhibitory
effect of fluoxetine on the development of dermatitis and to
obtain basic information about the usefulness of fluoxetine in the
treatment of AD.
MATERIALS AND METHODS
Animals
Six-week-old male BALB/c mice were obtained from Chongqing
Medical University Animal House Center and maintained at
Children’s Hospital of Chongqing Medical University Animal
Care Centre. Animals were housed in plastic cages in a
temperature-controlled (21◦C) colony room on a 12/12 h
light/dark cycle. Food and water were available ad libitum.
All experiments and procedures were approved by Chongqing
Medical University Animal Care and Use Committee. All efforts
were made to minimize the number of animals used.
Drugs
Fluoxetine and DNCB were purchased from Sigma-Aldrich Co.
(St. Louis, MO, USA). DNCB was dissolved in acetone-olive
oil (4:1, v/v) and fluoxetine was dissolved in 0.9% sterile saline
at a concentration of 10 mg/ml. The drug application and
experimental tests were performed in a double-blinded manner.
Induction of AD-Like Skin Lesions and
Fluoxetine Treatment
Induction of AD-like skin lesions procedure is described in
Figure 1 as described previously (Kim S. R. et al., 2014). The
backs of mice were shaved with an electric clipper and depilatory
cream a day before DNCB sensitization. The DNCB sensitization
and challenge were performed for 5 weeks. For the sensitization
process, a 1 cm × 1 cm gauze-attached patch was applied with
200 µl of 1% DNCB and attached to the shaved area twice
per week. Two weeks after sensitization, the back skin was
challenged with 200 µl of a 0.2% DNCB solution twice per week.
This procedure was repeated for 3 weeks and fluoxetine was
intraperitoneally administrated together. Behavioral tests were
performed within 3 days after DNCB and fluoxetine treatments.
At the end of the experiment, mice were sacrificed and samples
were collected to evaluate the effects of DNCB and fluoxetine
treatments (Figure 1).
Clinical Scoring of Skin Lesions
The severity of DNCB-induced skin lesions was clinically assessed
as previously described (Matsuda et al., 1997; Kim et al., 2008).
Briefly, the total clinical severity score for skin lesions was
calculated as the sum of the individual scores (0, no symptom; 1,
mild; 2, moderate; 3, severe) for the following four AD signs and
symptoms: erythema/hemorrhage, edema, excoriation/erosion,
and scaling/dryness.
Scratching Behavior
The animals were placed into an observation chamber for
10 min for acclimatization before the measurement of scratching
behavior. The scratching behavior was defined as the hind limb
scratches directed to the shaved area. The number of scratching
behaviors was counted for 30 min each time.
Elevated Plus Maze
Mice were placed in the center of a plus maze (each arm 30 cm)
that was elevated 50 cm above the floor with two opposite open
arms and two opposite closed arms (10-cm-tall walls on the
closed arms) arranged at right angles. The number of entries
and time spent in the closed and open arms were monitored for
10 min by ANY-Maze Video Tracking System. The maze was
cleaned with 70% ethanol and water between tests.
Forced Swimming
Mice were placed in a cylinder of water (temperature 24–25◦C;
10 cm in diameter, 30 cm in height) for 10 min. The depth of
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FIGURE 1 | Experimental protocol for induction of atopic dermatitis in mouse model. The back skin of mice was applied repeatedly with DNCB for 5 weeks
to induce AD. Fluoxetine was intraperitoneally administrated from the third week together with DNCB.
water was set to prevent animals from touching the bottom with
their hind limbs. The latency to immobility, which was defined
as floating or the least movement to maintain the head above
the water, was recorded by ANY-Maze Video Tracking System
(Stoelting Co.) from the side.
Histological Analysis
A portion of the skin biopsies were fixed in 4% paraformaldehyde.
The skin sections (4 µm thick) were stained with hematoxylin
and eosin (H&E) to evaluate the epidermal hyperplasia and the
other sections were stained with toluidine blue to evaluate the
infiltration of mast cells. Mast cells were counted in five parts of
high-power fields (HPF) at 400×magnification.
Measurement of Serum IgE
Blood samples were collected by cardiac puncture under
anesthesia, and sera were collected by centrifugation and stored
at −80◦C until use. Total IgE levels in plasma were determined
by sandwich ELISA using the Sigma mouse IgE ELISA kit (St.
Louis, MO, USA).
Cytokine Analysis by Real-Time PCR
Total RNA was extracted from spleen tissue with the TRIzol
reagent (Takara, Otsu, Shiga, Japan) according to the manufac-
turer’s instruction. The quantity and purity of total RNA were
determined with a Nanodrop reader (Nanodrop Technologies,
Wilmington, DE, USA). One microgram of total RNA was
converted to the first-strand DNA with PrimeScript RT reagent
Kit with gDNA Eraser (Takara, Otsu, Shiga, Japan) reverse
transcriptase (Takara, Otsu, Shiga, Japan) and RNAsin (Takara,
Otsu, Shiga, Japan). cDNA was amplified using gene-specific
primers and SYBR R© Premix Ex TaqTM II (Takara, Otsu,
Shiga, Japan). Primer sequences were as follows: Interferon-γ
(IFN-γ) (forward: 5′-CTCAAGTGGCATAGATGT-3′, reverse:
5′-GAGATAATCTGGCTCTGCAGGATT-3′); IL-2 (forward: 5′
-CTCTACAGCGGAAGCACAGCA-3′, reverse: 5′-TGCCGCA
GAGGTCCAAGTT-3′); IL-4 (forward: 5′-TGAACGAGGTCA
CAGGAGAAGG-3′, reverse: 5′-CACCTTGGAAGCCCTACA
GACA-3′); IL-13 (forward: 5′-AGCATGGTATGGAGTGTGG
ACCTG-3′, reverse: 5′-CAGTTGCTTTGTGTAGCTGAGCAG-
3′); β-actin (forward: 5′-GCACCACACCTTCTACAATGAGC-
3′, reverse: 5′-GGATAGCAGCCTGGATAGCAAC-3′). The
relative expression levels of target genes were normalized using
β-actin as an internal control.
Statistical Analyses
All data are expressed as the mean ± SEM. Statistical analysis
of the results were performed by one-way analysis of variance
(ANOVA) followed by Turkey’s test. Significance level was set at
p < 0.05.
RESULTS
Chronic Fluoxetine Treatment Alleviates
DNCB-Induced AD Symptoms
Previous studies have shown that paroxetine, a selective
SSRI, is effective in the treatment of AD in both animal
model and patients, with no apparent side-effects (Zylicz
et al., 2003; Jiang et al., 2007; Stander et al., 2009). To
determine whether fluoxetine is effective in the treatment of
AD-like skin lesions, we chronically treated AD mice with
fluoxetine (10 mg/kg, i.p.; Figure 1). Consistent with previous
reports (Kim H. et al., 2014; Kim S. R. et al., 2014; Yoon
et al., 2015), AD-like lesions developed following repeated
application of DNCB to the back skin (Figure 2A). More
importantly, chronic fluoxetine administration dramatically
alleviated skin lesions (Figure 2A). To further compare the
skin lesions of the mice with those of human AD (Mihm
et al., 1976; Piloto Valdes et al., 1990), clinical severity of the
dermatitis was scored as previously described (Leung et al.,
1990). The result showed that DNCB treatment significantly
increased the skin lesion score compared with normal control,
whereas the skin lesion score was significantly decreased
after fluoxetine treatment (control: n = 10; DNCB: n = 10;
DNCB+fluoxetine: n = 14; Figure 2B). In addition, chronic
fluoxetine treatment significantly suppressed DNCB-induced
scratching behaviors (control: n = 10; DNCB: n = 10;
DNCB+fluoxetine: n = 14; Figure 2C). Taken together, these
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FIGURE 2 | The preventive effect of chronic fluoxetine treatment on
AD-like skin lesions induced by DNCB treatment. (A) Photographs
showing skin lesions in the different groups of experimental mice. (B) The
severity of clinical symptoms of the skin lesions was evaluated
macroscopically and calculated as the sum of the individual scores once a
week for the following four AD signs and symptoms: erythema/hemorrhage,
edema, excoriation/erosion and scaling/dryness. (C) The frequency of
scratching behavior was observed and calculated once a week in the different
treatment group. n = 10 for control and DNCB, n = 14 for DNCB+fluoxetine.
∗∗P < 0.01 compared with control, and #p < 0.05 compared with DNCB
group.
results suggest that chronic fluoxetine treatment alleviates the
DNCB-induced skin lesions.
Chronic Fluoxetine Treatment Reduces
Depressive- and Anxiety-Like Behaviors
in AD Mice
A growing body of evidence has shown that AD in both
adolescence and adulthood increases the risk of developing
major depression and anxiety disorders in later life (Wahlgren,
1992; Ginsburg et al., 1993; Hashiro and Okumura, 1997;
Cheng et al., 2015), and fluoxetine has been widely used as
an antidepressant agent in clinic. Thus, we next introduced
different behavioral tests, including forced swimming and
elevated plus maze, to determine whether the alleviating effect
of fluoxetine on AD is associated with its antipsychotic effect.
Compared to normal controls, AD mice displayed apparent
depressive-like symptom, as reflected by much shorter latency
to immobility during forced swimming test (control: n = 10,
186.8 ± 5.0 s; DNCB: n = 10, 157.2 ± 10.4 s, p < 0.05
vs. control; Figure 3A). In agreement with an anti-depressive
effect of fluoxetine, it succeeded in abolishing the influence
of DNCB on depressive behavior (DNCB+fluoxetine: n = 14,
228.3 ± 15.2 s, p < 0.05 vs. control, p < 0.01 vs. DNCB;
Figure 3A).
Next, using elevated plus maze paradigm, we tested the effect
of fluoxetine on anxiety-like behavior in AD. The results showed
that both the number of entry into open arms (control: n = 10,
25.5 ± 3.9; DNCB: n = 10, 11.1 ± 1.5, p < 0.05 vs. control;
Figure 3B) and the time spent in open arms (control: n = 10,
40.2 ± 5.5 s; DNCB: n = 10, 11.1 ± 3.1 s, p < 0.05 vs. control;
Figure 3C) were significantly reduced in DNCB-treated mice
during elevated plus maze test. Similar to forced swimming test,
chronic fluoxetine treatment was able to restore the number of
entry into the open arms (DNCB+fluoxetine: n= 14, 34.9± 4.9,
p< 0.05 vs. control, p< 0.01 vs. DNCB; Figure 3B) and the time
in open arms (DNCB+fluoxetine: n= 14, 61.7± 10.8 s, p< 0.05
vs. control, p < 0.01 vs. DNCB; Figure 3C) to control levels,
indicating chronic fluoxetine administration reduces anxiety
during AD development.
Chronic Fluoxetine Treatment
Suppresses Tissue Inflammation and the
Accumulation of Mast Cells in AD-Like
Skin Lesions
It has been widely accepted that AD is a common chronic
inflammatory skin disease. We next wanted to determine the
alterations of tissue inflammation and the accumulation of mast
cells in AD-like skin lesions. Consistent with previous reports
(Kim S. R. et al., 2014; Yoon et al., 2015), histopathological
examination showed that the skins of the DNCB-treated group
showed markedly epidermal hyperplasia as compared to the
normal group, whereas this hyperplasia was significantly reduced
by chronic fluoxetine treatment (control: n = 10, 17.0 ± 1.8 µm;
DNCB: n = 10, 83.4 ± 13.2 µm, p < 0.01 vs. control;
DNCB+fluoxetine: n = 14, 54.9 ± 5.8 µm, p < 0.01 vs.
control, p < 0.05 vs. DNCB; Figures 4A,B). Similarly, the
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FIGURE 3 | Effects of chronic fluoxetine treatment on depressive- and
anxiety-like behaviors induced by DNCB treatment. (A) The latency to
immobility was measured during forced swimming test in the different groups
of experimental mice. Both the number of entries into open arms (B) and the
time spent in open arms (C) were measured during elevated plus maze test.
n = 10 for control and DNCB, n = 14 for DNCB+fluoxetine. ∗P < 0.05,
∗∗P < 0.01.
number of mast cells in the dermis of DNCB-treated mice
was markedly increased as compared to the normal group,
whereas this increment was significantly suppressed by chronic
fluoxetine treatment (control: n = 10, 8.5 ± 1.7; DNCB:
n = 10, 88.0 ± 8.5, p < 0.01 vs. control; DNCB+fluoxetine:
n = 14, 57.3 ± 7.8, p < 0.01 vs. control, p < 0.05 vs. DNCB;
Figures 4C,D).
Chronic Fluoxetine Treatment Inhibits
DNCB-Induced Serum IgE Elevation
Since serum IgE level is correlated with the severity of
AD (Arshad and Holgate, 2001; Belloni et al., 2008; Ibler
and Jemec, 2015; Montes-Torres et al., 2015), and the level
of IgE is associated with Th2 or Th1 immunity (Snapper
and Paul, 1987), we examined the serum level of IgE to
evaluate the effect of fluoxetine on systemic Th1 and Th2
immunities in DNCB-treated mice. As shown in Figure 5,
the serum level of IgE was markedly increased in the DNCB-
treated group compared to normal control (control: n = 4,
11.1 ± 1.9 µg/ml; DNCB: n = 6, 19.6 ± 2.8 µg/ml, p < 0.01
vs. control; Figure 5). Chronic fluoxetine treatment restored the
serum IgE to normal control level (DNCB+fluoxetine: n = 5,
11.6 ± 0.4 µg/ml, p > 0.05 vs. control, p < 0.05 vs. DNCB;
Figure 5).
Chronic Fluoxetine Treatment Reduces
Spleen Cytokines in AD Mice
In the past decades, SSRIs including fluoxetine have been shown
to exert several immunological effects, such as alteration of
cytokine secretion (Janssen et al., 2010; Gobin et al., 2013,
2014). To evaluate the effects of fluoxetine on Th1 and Th2
immunities in AD, we examined the expression of IL-2, IFN-
γ, IL-4, and IL-13 mRNAs in the spleen of experimental
mice. The results showed that the IL-4 (control: n = 4,
100.0 ± 14.7; DNCB: n = 4, 288.6 ± 7.1, p < 0.01 vs.
control; Figure 6A) and IL-13 (control: n = 6, 100.0 ± 6.5;
DNCB: n = 5, 212.5 ± 36.1, p < 0.05 vs. control; Figure 6B)
mRNA expressions were dramatically increased, whereas the IL-
2 (control: n = 6, 100.0 ± 18.0; DNCB: n = 6, 84.0 ± 11.5,
p > 0.05 vs. control; DNCB+fluoxetine: n = 5, 99.1 ± 12.6,
p > 0.05 control, p > 0.05 vs. DNCB; Figure 6C) and IFN-γ
(control: n = 6, 100.0 ± 17.6; DNCB: n = 6, 126.8 ± 4.4,
p > 0.05 vs. control; DNCB+fluoxetine: n = 6, 102.6 ± 12.9,
p > 0.05 control, p > 0.05 vs. DNCB; Figure 6D) mRNA
expressions remained unchanged in DNCB-treated mice as
compared to the normal group. More importantly, chronic
fluoxetine treatment suppressed the DNCB-induced increase of
IL-4 (DNCB+fluoxetine: n = 5, 145.2 ± 42.3, p > 0.05 control,
p < 0.05 vs. DNCB; Figure 6A) and IL-13 mRNA expressions
(DNCB+fluoxetine: n = 6, 132.1 ± 27.3, p > 0.05 control,
p < 0.05 vs. DNCB; Figure 6B)
DISCUSSION
In the present study, we confirm that repeated DNCB treatment
induces the AD-like pathology, and demonstrate that chronic
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FIGURE 4 | Histopathological findings showing the preventive effect of chronic fluoxetine treatment on DNCB-induced AD-like skin lesions. (A) Skin
sections (4 µm thick) were stained with H&E. Scale bar is 100 µm. (B) Epidermal thickness was analyzed in the H&E-stained sections. (C) Skin sections were
stained with toluidine blue. Scale bar is 50 µm. (D) The number of mast cells were counted in five high-power fields (HPF) chosen at random in each toluidine
blue-stained slide by three different pathologists. n = 10 for control and DNCB, n = 14 for DNCB+fluoxetine. ∗P < 0.05, ∗∗P < 0.01.
FIGURE 5 | Effects of chronic fluoxetine treatment on serum levels of
lgE in DNCB-treated mice. Total serum levels of total IgE were determined
by ELISA. n = 4–6 in each group. ∗P < 0.05.
fluoxetine treatment reduces DNCB-induced inflammatory
response and subsequently ameliorate AD symptoms in BALB/c
mice. Therefore, our current results indicate that fluoxetine may
effectively prevent AD symptoms.
It has been reported that SSRI such as paroxetine can
inhibit the development of AD-like lesions in NC/Nga mice
and alleviate chronic pruritus in patients (Zylicz et al., 2003;
Jiang et al., 2007; Stander et al., 2009). However, the underlying
mechanism of antipruritic effect of SSRI remains unclear at
present. It is well documented that AD is an inflammatory skin
disease characterized by pruritic and eczematous skin lesions,
extensive inflammatory cell infiltration and release of pro-
inflammatory mediators (Morar et al., 2006). Previous study
has shown that IgE expression causes both acute and chronic
phase skin inflammations, suggesting that the upregulation
of total serum IgE may be a hallmark of AD (Arshad and
Holgate, 2001). Further study has shown that the level of
IgE is associated with Th2 or Th1 immunity, in turn, Th2
has powerful effect in stimulating the expression of IgE
(Snapper and Paul, 1987). Therefore, although the mechanism
for the anti-AD action of fluoxetine remains unclear, the
downregulation of serum IgE and Th2 immunity may be a
principal mechanism for the fluoxetine action. Indeed, in the
present study, we found that chronic fluoxetine treatment
reduced total IgE level and suppressed Th2 such as IL-4
and IL-13 mRNA expressions in DNCB-treated mice. This
hypothesis is further supported by more recent reports. For
example, SSRIs including fluoxetine have been shown to exert
several immunosuppressive effects, such as decreased lymphocyte
proliferation and reduced pro-inflammatory cytokine secretion
(Janssen et al., 2010; Gobin et al., 2013, 2014). On the other
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FIGURE 6 | Effects of chronic fluoxetine treatment on mRNA expressions of cytokines. IL-4 (A), IL-13 (B), IL-2 (C) and IFN-γ (D) mRNA expressions were
determined by real-time PCR. n = 4–6 in each group. ∗P < 0.05, ∗∗P < 0.01.
hand, fluoxetine significantly decreases lymphocyte proliferation,
which is resulted from elevated central serotonin (5-HT)
neurotransmission and activation of central 5-HT2 receptors
(Pellegrino and Bayer, 2002). In addition, fluoxetine also
can exert immunosuppressive effect via suppressing intra-
cellular Ca2+ signaling in Jurkat T lymphocytes through
depletion of Ca2+ from intracellular stores (Gobin et al.,
2015).
Alternatively, fluoxetine may modulate psycho-emotion
and subsequently prevent AD symptoms. Previous study has
shown that the majority of patients with AD are subjected
to psychological stress, and in turn, stress aggravates
their pruritus, suggesting that pruritus might be closely
related with emotional distress in AD (Wahlgren, 1992).
Fluoxetine is frequently used in clinic to treat neuropsychiatric
disorders, such as major depressive disorder, obsessive-
compulsive disorder, post-traumatic stress disorder, and
anxiety disorder (McIntyre and Katzman, 2003; Pinna et al.,
2009). Thus, it is reasonable to assume that fluoxetine may
play anti-AD action through the inhibition of psychological
stress. Indeed, in the present study, we found that chronic
fluoxetine treatment led to a significant decrease in DNCB-
induced depressive- and anxiety-like behaviors (Figure 3).
Notably, chronic treatment with fluoxetine impairs adult
neurogenesis and locomotor activity in mice (Ohira and
Miyakawa, 2011; Zheng et al., 2011). Thus, future experiments
determining the potential side effects of chronic treatment
with fluoxetine will be helpful to fluoxetine in the treatment
of AD.
In summary, we demonstrate that chronic fluoxetine
treatment is an effective means to reduce DNCB-induced
scratching bouts, depressive/anxiety-like behaviors, skin lesions
and serum IgE levels in mice model of AD, and these effects
are mediated by regulating pro-inflammatory cytokines, such as
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IL-4 and IL-13. These results suggest that fluoxetine may be a
potential therapeutic agent against AD in clinic; nevertheless,
further investigations would be necessary to clarify its molecular
mechanisms of action in AD.
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